<DOC>
	<DOCNO>NCT00825149</DOCNO>
	<brief_summary>This open-label , randomize , phase Ib study ass safety efficacy obinutuzumab give combination FC ( fludarabine cyclophosphamide ) CHOP ( cyclophosphamide , doxorubicin , vincristine prednisolone ) bendamustine induction chemotherapy participant Cluster Differentiation ( CD ) 20+ B-cell Follicular Lymphoma ( FL ) . Participants complete response partial response induction therapy may receive maintenance therapy every 3 month 2 year disease progression , whichever come first . All participant induction period study safety follow-up visit 28 day complete last dose obinutuzumab + chemotherapy , follow least 2 year , unless treat maintenance discontinue study prior time point . Participants complete/discontinue maintenance therapy also follow period 2 year receive last dose obinutuzumab progression/new antilymphoma treatment .</brief_summary>
	<brief_title>A Study Obinutuzumab Combination With Chemotherapy Participants With CD20+ B-Cell Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Either CD20+ R/R Bcell follicular nonHodgkin 's lymphoma ( maximum 2 prior chemotherapy regimen ) CD20+ Bcell follicular nonHodgkin 's lymphoma prior systemic therapy Must least one bidimensionally measurable lesion ( great [ &gt; ] 1.5 centimeter [ cm ] large dimension compute tomography [ CT ] scan ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 For R/R participant recruit Obinutuzumab + CHOP regimen , prior use anthracyclines . For R/R participant recruit Obinutuzumab + FC regimen , immediate prior treatment contain fludarabine fluoropyrimidines . For firstline recruit participant , prior systemic therapy Prior administration rituximab within 56 day study entry , 3 month radioimmunotherapy Central nervous system lymphoma History malignancy within 2 year study entry could affect compliance protocol interpretation result Known active bacterial , viral ( include human immunodeficiency virus [ HIV ] ) , fungal , mycobacterial , infection ( exclude fungal infection nail bed ) major episode infection require hospitalization treatment IV antibiotic within 4 week dose Contraindication individual component chemotherapy ( per local prescribe information ) , select chemotherapy combination ( FC , CHOP bendamustine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>